Wes Warnock News Today

DALLAS--(BUSINESS WIRE)--Nov 1, 2023--

DALLAS--(BUSINESS WIRE)--Oct 5, 2023--

DALLAS, Texas & MONTREAL, Canada--(BUSINESS WIRE)--Aug 31, 2023--

DALLAS and MONTREAL, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Flowserve Corporation (NYSE: FLS) and Velan Inc. (“Velan”) (TSX: VLN) today announced that they...

GlobeNewswire Press Release.

Alcon Inc. Swiss: Alcon Reports First Quarter 2021 Results Strong commercial execution drives the global launch of new product innovations Substantially completes separation process Full year guidance: sales of $7.8 to $8.0 billion and core diluted EPS of $1.85 to $1.95 Regulatory News: Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2021. For the first quarter of 2021, worldwide sales were $1.9 billion, an increase of 5% ...

Alcon Inc. Swiss: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza Builds on companys ophthalmic pharmaceutical manufacturing expertise Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza The acquisition of Simbrinza combined with the companys existing over-the-counter (OTC) eye drops will give ...

Press release content from Business Wire. The AP news staff was not involved in its creation. Alcon Shareholders Approve All Binding Resolutions at the 2021 Annual General Meeting April 28, 2021 GMT GENEVA--(BUSINESS WIRE)--Apr 28, 2021-- Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the results of its 2021 Annual General Meeting. Given the global COVID-19 outbreak, Alcon previously directed shareholders to send their voti...

Alcon Inc. Investors: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza Builds on companys ophthalmic pharmaceutical manufacturing expertise Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza The acquisition of Simbrinza combined with the companys existing over-the-counter (OTC) eye drops will give Alcon a stron...

Alcon Inc. Investors: Alcon Reports Fourth Quarter and Full Year 2020 Results Continued recovery resulted in full year sales of $6.8 billion, 8% below last year New product launches driving market share gains; executing on strategic initiatives Generated $823 million in cash from operations and $350 million in free cash flow Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the fourth quarter and full year ended December 31, 2020. For the fourth quarter of...